Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,230,000 shares, an increase of 58.5% from the October 15th total of 776,000 shares. Approximately 3.8% of the shares of the company are sold short. Based on an average daily volume of 618,200 shares, the short-interest ratio is presently 2.0 days.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in shares of Werewolf Therapeutics in the 3rd quarter worth about $29,000. Point72 DIFC Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at approximately $34,000. Rhumbline Advisers purchased a new stake in Werewolf Therapeutics during the second quarter valued at $79,000. American Century Companies Inc. grew its holdings in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares during the last quarter. Finally, Murchinson Ltd. purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at about $152,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Stock Performance

HOWL stock traded down $0.12 during midday trading on Thursday, hitting $1.93. The stock had a trading volume of 563,994 shares, compared to its average volume of 376,794. The firm has a market capitalization of $86.00 million, a price-to-earnings ratio of -1.26 and a beta of 0.41. The stock has a 50-day simple moving average of $2.27 and a 200 day simple moving average of $2.92. Werewolf Therapeutics has a 52 week low of $1.66 and a 52 week high of $8.19. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.